Athens, 5/5/2025
The Medline Company is pleased to announce that, as of May 5, 2025, the innovative continuous glucose monitoring (CGM) device SIBIONICS GS1 has been officially included in the reimbursement scheme of the National Organization for Healthcare Services Provision (EOPYY).
The reimbursement fully or partially covers the use of the device for the following patient groups:
- Individuals with Type 1 Diabetes, regardless of age.
- Pregnant women with Gestational Diabetes, for the duration of pregnancy and as long as there is a documented medical need for glucose monitoring.
The SIBIONICS GS1 device provides accurate and continuous glucose measurements without the need for fingerstick testing, thereby enhancing quality of life and improving the effectiveness of diabetes management.
For information regarding the reimbursement process, medical prescriptions, and required documentation, please contact our Customer Support Department at +30 216 939 5545 or via email at sibionics@the-medline.company.
The Medline Company remains committed to supporting the diabetes community by delivering modern solutions and cutting-edge technologies.
Kind regards,
The Medline Company
